Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19.

Journal of clinical pharmacology - 1 Nov 2017

Yamamoto Takehito, Furihata Kenichi, Hisaka Akihiro, Moritoyo Takashi, Ogoe Kazuaki, Kusayama Shizuko, Motohashi Keiju, Mori Akiko, Iwatsubo Takeshi, Suzuki Hiroshi

Abstract excerpt

In this study, impact of a polymorphism of CYP2C19 on drug-drug interaction (DDI) was examined for etizolam. The effect of itraconazole (a strong CYP3A inhibitor) on the pharmacokinetics of etizolam (a substrate of CYP2C19 and CYP3A) was assessed in both extensive metabolizers (EMs) and poor metabolizers (PMs) of CYP2C19. Sixteen participants (8 EMs and 8 PMs) received a single oral dose of etizolam (0.25 mg) on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diazepam

Share to Drug Interactions

Share to Genotype

Share to Itraconazole

Share to Microsomes, Liver

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 28679023
DOI: 10.1002/jcph.956

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19.PMID 28679023Read ↗

Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity.Semantic proximity Read ↗

Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.Semantic proximity Read ↗

<i><scp>CYP</scp>2C19</i> Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?Semantic proximity Read ↗

Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacySemantic proximity Read ↗

Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro.Semantic proximity Read ↗

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.Semantic proximity Read ↗

The impact of CYP2C19 genotype on phenoconversion by concomitant medicationSemantic proximity Read ↗

The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.Semantic proximity Read ↗

Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.Semantic proximity Read ↗

Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.Semantic proximity Read ↗

Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 *1 and *2 (rs4244285, 681G>A) alleles in vitro.Semantic proximity Read ↗

Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.